Amgen has launched its Kanjinti (trastuzumab-anns) biosimilar rival to Genentech's Herceptin and its Mvasi (bevacizumab-awwb) biosimilar version of Genentech's Avastin in the US.
Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
